Differential role of Fas/Fas ligand interactions in cytolysis of primary and metastatic colon carcinoma cell lines by human antigen-specific CD8+ CTL

被引:43
作者
Bergmann-Leitner, ES [1 ]
Abrams, SI [1 ]
机构
[1] NCI, Tumor Immunol & Biol Lab, Div Basic Sci, NIH, Bethesda, MD 20892 USA
关键词
D O I
10.4049/jimmunol.164.9.4941
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We have previously identified mutated ras peptides reflecting the glycine to valine substitution at position 12 as HLA-A2-restricted, CD8(+) CTL neo-epitopes. CTL lines produced against these peptide epitopes lysed the HLA-A2(+) Ag-bearing SW480 primary colon adenocarcinoma cell line, although IFN-gamma. treatment of the targets was necessary to achieve efficient cytotoxicity. Here, we compared the lytic phenotype of the SW480 cell line to its metastatic derivative, SW620, as an in vitro paradigm to further characterize the nature of a HLA class I-restricted, Ag-specific CTL response against neoplastic cell lines of primary and metastatic origin. Although both colon carcinoma cell lines were lysed by these Ag-specific CTL following IFN-gamma pretreatment, the mechanisms of lysis were distinct, which reflected differential levels of sensitivity to the Fas pathway. Whereas IFN-gamma pretreatment rendered SW480 cells sensitive to both Fas-dependent and -independent (perforin) pathways, SW620 cells displayed lytic susceptibility to Fas-independent mechanisms only, Moreover, pretreatment of SW480 cells with the anti-colon cancer agent, 5-fluorouracil (5-FU), led to enhanced Fas and ICAM-1 expression and triggered Ag-specific CTL-mediated lysis via Fas- and perforin-based pathways. In contrast, these phenotypic and functional responses were not observed with SW620 cells. Overall, these data suggested that 1) IFN-gamma, and 5-FU may enhance the lytic sensitivity of responsive colon carcinoma cells to immune effector mechanisms, including Fas-induced lysis; 2) the malignant phenotype may associate with resistance to Fas-mediated lysis in response to Ag-specific T cell attack; and 3) if Ag-specific CTL possess diverse lytic capabilities, this may overcome, to some extent, the potential "escape" of Fas-resistant carcinoma cells.
引用
收藏
页码:4941 / 4954
页数:14
相关论文
共 47 条
  • [1] ABRAMS SI, 1991, J IMMUNOL, V146, P405
  • [2] Generation of stable CD4+ and CD8+ T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations
    Abrams, SI
    Khleif, SN
    Bergmann-Leitner, ES
    Kantor, JA
    Chung, Y
    Hamilton, JM
    Schlom, J
    [J]. CELLULAR IMMUNOLOGY, 1997, 182 (02) : 137 - 151
  • [3] ALBINI A, 1987, CANCER RES, V47, P3239
  • [4] BEDNAREK MA, 1991, J IMMUNOL, V147, P4047
  • [5] Identification of a human CD8+ T lymphocyte neo-epitope created by a ras codon 12 mutation which is restricted by the HLA-A2 allele
    Bergmann-Leitner, ES
    Kantor, JA
    Shupert, WL
    Schlom, J
    Abrams, SI
    [J]. CELLULAR IMMUNOLOGY, 1998, 187 (02) : 103 - 116
  • [6] Drug resistance results in alterations in expression of immune recognition molecules and failure to express Fas (CD95)
    Bhushan, A
    Kupperman, JL
    Stone, JE
    Kimberly, PJ
    Calman, NS
    Hacker, MP
    Birge, RB
    Tritton, TR
    Newell, MK
    [J]. IMMUNOLOGY AND CELL BIOLOGY, 1998, 76 (04) : 350 - 356
  • [7] Cellular responses to interferon-gamma
    Boehm, U
    Klamp, T
    Groot, M
    Howard, JC
    [J]. ANNUAL REVIEW OF IMMUNOLOGY, 1997, 15 : 749 - 795
  • [8] GENETIC MECHANISMS IN TUMOR INITIATION AND PROGRESSION .10. THE RAS GENE FAMILY AND HUMAN CARCINOGENESIS
    BOS, JL
    [J]. MUTATION RESEARCH, 1988, 195 (03): : 255 - 271
  • [9] Matrix metalloproteinase inhibitors in the treatment of cancer
    Brown, PD
    [J]. MEDICAL ONCOLOGY, 1997, 14 (01) : 1 - 10
  • [10] ACTIVATION OF KI-RAS 2 GENE IN HUMAN-COLON AND LUNG CARCINOMAS BY 2 DIFFERENT POINT MUTATIONS
    CAPON, DJ
    SEEBURG, PH
    MCGRATH, JP
    HAYFLICK, JS
    EDMAN, U
    LEVINSON, AD
    GOEDDEL, DV
    [J]. NATURE, 1983, 304 (5926) : 507 - 513